RT Journal
A1 Shuldiner AR, Vesely MR, Fisch A
T1 CYp2c19 genotype and cardiovascular events
JF JAMA
JO JAMA
YR 2012
FD April 11
VO 307
IS 14
SP 1482
OP 1485
DO 10.1001/jama.2012.443
UL http://dx.doi.org/10.1001/jama.2012.443
AB 
To the Editor:  The recent meta-analysis by Dr Holmes and colleagues1 concluding that CYP2C19 genotype is not a significant predictor of clinical outcomes in patients treated with clopidogrel contrasts with a previous meta-analysis2 and a large body of pharmacokinetic and pharmacodynamic evidence,3 including a genome-wide association study.4 The authors cite small-study bias and inability to evaluate effect modification in treatment-only studies as reasons underlying the discrepant findings.